Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Payables (2017 - 2025)

Historic Payables for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $13.6 million.

  • Innate Pharma's Payables fell 2026.22% to $13.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $13.6 million, marking a year-over-year decrease of 2026.22%. This contributed to the annual value of $17.3 million for FY2024, which is 588.68% down from last year.
  • Per Innate Pharma's latest filing, its Payables stood at $13.6 million for Q2 2025, which was down 2026.22% from $17.1 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Payables registered a high of $32.7 million during Q4 2021, and its lowest value of $13.6 million during Q2 2025.
  • In the last 5 years, Innate Pharma's Payables had a median value of $19.9 million in 2022 and averaged $20.1 million.
  • As far as peak fluctuations go, Innate Pharma's Payables plummeted by 9992.28% in 2021, and later soared by 382.06% in 2023.
  • Over the past 5 years, Innate Pharma's Payables (Quarter) stood at $32.7 million in 2021, then crashed by 34.73% to $21.3 million in 2022, then dropped by 14.17% to $18.3 million in 2023, then fell by 6.58% to $17.1 million in 2024, then dropped by 20.32% to $13.6 million in 2025.
  • Its Payables was $13.6 million in Q2 2025, compared to $17.1 million in Q4 2024 and $17.1 million in Q2 2024.